Kazia Therapeutics - Multiple paxalisib data points expected in Q4
Kazia expects to release multiple data points from its paxalisib program in Q4 CY21. These include final data from the 30-patient Phase II trial in...
514 Views
Kazia Therapeutics - Multiple paxalisib data points expected in Q4
Kazia expects to release multiple data points from its paxalisib programme in Q4 CY21. These include final data from the 30-patient Phase II trial...
565 Views
Kazia Therapeutics: Pivotal Phase 3 Study Underway
Kazia Therapeutics Pivotal phase 3 study underway Kazia Therapeutics (ASX:KZA) is an oncology focused drug development company with lead...
1.1k Views
Video: Kazia Therapeutics - overview and update with CEO James Garner
Kazia Therapeutics (KZA) is an oncology-focused drug development company. Its drug candidates are designed to treat diseases which are poorly...
425 Views
Kazia Therapeutics - Bringing a vetted drug class to the brain
We are reinitiating on Kazia Therapeutics, which is entering late-stage trials for its lead product, paxalisib, for glioblastoma multiforme (GBM)....
95 Views
No more insights